Allogene Therapeutics Presents Preclinical Research Highlighting a Novel TurboCAR™ T Cell Technology Designed to Overcome Immune Suppression in Solid Tumors at the American Association for Cancer Research (AACR) Virtual 2021 Meeting
Allogene Therapeutics (Nasdaq: ALLO) recently showcased preclinical data at the AACR Annual Meeting, revealing that its TurboCAR™ technology platform can enhance treatment efficacy for solid tumors by selectively activating cytokine signaling in CAR T cells. New TurboCAR constructs respond to PDL1/2, enabling them to overcome immunosuppressive challenges in the tumor microenvironment. This advancement could broaden the applicability of AlloCAR T™ therapies, positioning Allogene as a leader in both hematologic and solid tumor treatments.
- Expansion of TurboCAR technology enhances treatment for solid tumors.
- New constructs can overcome immunosuppressive signals in the tumor microenvironment.
- None.
- Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells
- New TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making Cytokine Activation Dependent Upon the Tumor Microenvironment and Overcoming PDL1/2 Inhibition
- Results Illustrate the Potential to Broaden the Application of the TurboCAR Platform into Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced preclinical data at the American Association for Cancer Research (AACR) Annual Meeting that expands the utility of its TurboCAR™ technology platform to address specific biology of solid tumor oncology.
Allogene’s internally-developed TurboCAR technology platform is capable of delivering cytokine activation signaling selectively to CAR T cells. As the potential next generation of AlloCAR T therapies, TurboCARs can be tailored with signaling domains from different cytokine receptors to enhance T cell activation and potentially improve efficacy, overcome exhaustion, and reduce cell dose requirements. The data presented at AACR demonstrate the ability to engineer PD1 TurboCARs which confer cytokine signaling that is inducible upon binding to PDL1/2 in the tumor microenvironment or when stimulated with an anti-PD1 antibody. In addition to supplying cytokine signaling, these TurboCARs are designed to overcome the inherent challenges in solid tumors associated with the immuno-suppressive tumor microenvironment (TME) and turn the suppressive signals into positive signals.
“We are very excited about the potential to expand our TurboCAR technology platform to maximize its impact in allogeneic cell therapy. We believe our preclinical findings shared at AACR represent a powerful differentiator that will allow Allogene to remain at the forefront of innovation in both hematologic cancers and solid tumors,” said Barbra Sasu, Ph.D., Chief Scientific Officer of Allogene.
Title: PD1 TurboCAR™ T cells: PD1-resistant CAR T cells with programmable cytokine signaling outputs
Date: April 10, 2021 at 8:30 a.m. ET
E-Poster Session: Immunology
Session Title: Adoptive Cell Therapy
Abstract Number: 1519
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability of TurboCARs to enhance T cell activation and potentially improve efficacy, overcome exhaustion, and reduce cell dose requirements; the ability to overcome the inherent challenges in solid tumors associated with the immuno-suppressive TME and turn the suppressive signals into positive signals; the ability to manufacture AlloCAR T™ therapies; and the potential benefits of AlloCAR T therapies. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-K for the year ended December 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR™, AlloCAR T™ and TurboCAR™ are trademarks of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
What is Allogene Therapeutics' TurboCAR technology?
How does TurboCAR technology help in treating solid tumors?
What were the results presented at the AACR Annual Meeting?
What is the significance of the findings for Allogene's future?
